HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Strength training and albuterol in facioscapulohumeral muscular dystrophy.

AbstractBACKGROUND:
In animals and healthy volunteers beta2-adrenergic agonists increase muscle strength and mass, in particular when combined with strength training. In patients with facioscapulohumeral muscular dystrophy (FSHD) albuterol may exert anabolic effects. The authors evaluated the effect of strength training and albuterol on muscle strength and volume in FSHD.
METHODS:
Sixty-five patients were randomized to strength training of elbow flexors and ankle dorsiflexors or non-training. After 26 weeks albuterol (sustained-release, 8 mg BID) was added in a randomized, double-blind, placebo-controlled design. Primary outcome was maximum voluntary isometric strength (MVIC) at 52 weeks. Secondary outcomes comprised dynamic strength and muscle volume.
RESULTS:
Training and albuterol were well tolerated. Training of elbow flexors did not result in a significant effect on MVIC, but dynamic strength improved significantly. Elbow flexor MVIC strength increased significantly in albuterol vs placebo treated patients. Ankle dorsiflexor strength decreased in all groups. Eleven out of twelve non-trained muscles in the albuterol group showed a positive effect on MVIC compared to the placebo group (p < 0.05 in seven muscle groups). Muscle volume decreased in the placebo-treated, and increased in the albuterol-treated patients. No synergistic or antagonistic effects were observed between training and albuterol.
CONCLUSIONS:
In FSHD strength training and albuterol appear safe interventions with limited positive effect on muscle strength and volume. Consequences of prolonged use are presently unclear, which precludes routine prescription.
AuthorsE L van der Kooi, O J M Vogels, R J G P van Asseldonk, E Lindeman, J C M Hendriks, M Wohlgemuth, S M van der Maarel, G W Padberg
JournalNeurology (Neurology) Vol. 63 Issue 4 Pg. 702-8 (Aug 24 2004) ISSN: 1526-632X [Electronic] United States
PMID15326246 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Adrenergic beta-Agonists
  • Delayed-Action Preparations
  • Albuterol
Topics
  • Adrenergic beta-Agonists (administration & dosage, therapeutic use)
  • Adult
  • Albuterol (administration & dosage, therapeutic use)
  • Ankle Joint
  • Combined Modality Therapy
  • Delayed-Action Preparations
  • Double-Blind Method
  • Elbow Joint
  • Female
  • Humans
  • Male
  • Middle Aged
  • Muscular Dystrophy, Facioscapulohumeral (drug therapy, therapy)
  • Physical Endurance
  • Respiratory Function Tests
  • Treatment Outcome
  • Weight Lifting

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: